Sagong, Min
Kim, Jae Hui
Woo, Se Joon
Kim, Yu Cheol
Cho, Heeyoon
Lee, Young Hoon
Byon, Iksoo
Jo, Young Joon
Chin, Hee Seung
Kim, Jeonghee
Chae, Jae Eun
Kang, Se Woong
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 16 May 2024
Accepted: 13 August 2024
First Online: 5 September 2024
Declarations
:
: Min Sagong reports honoraria from Allergan, Bayer, Novartis, and Roche for lecture fees, consultancy, and board membership and reports research grants from Allergan, Bayer, and Novartis. Jae Hui Kim reports grants from Novartis and Bayer. Se Joon Woo is a consultant of Samsung Bioepis, Alteogen, Curacle, Novelty Nobility, Sometech, and Pharmabcine; reports grants from Samsung Bioepis, Curacle, Alteogen, Bayer, Novartis, Geneuintech and Roche; reports lecture fees from Novartis, Bayer, Allergan/AbbVie, Roche and Samil; and owns equity of RetiMark and Panolos Bioscience. Yu Cheol Kim is a consultant for Novartis and Bayer; received honoraria from Allergan, Bayer, and Novartis; and research grants from Chong Kun Dang Pharm., SCD Pharm., Bayer, and Novartis. Heeyoon Cho reports lecture fees and consultancy from Allergan, Bayer, and Novartis. Young Hoon Lee and Hee Seung Chin have no financial disclosures. Iksoo Byon is a consultant/advisor for Novartis, Bayer, and AIinsight Inc and reports grants from Novartis and Busan Technopark. Young Joon Jo reports grants from Bayer and Novartis. Jeonghee Kim is an employee of Novartis Korea Ltd. Jae Eun Chae is an employee of LSK Global Pharma Services, Korea. Se Woong Kang has served on advisory boards for Novartis, Bayer, Allergan, Alcon, and Samchundang and has received consultancy fees and payments for lectures from these companies.
: This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline and adhered to the ethical principles derived from the Declaration of Helsinki. Each IRB/ IEC reviewed and approved the study protocol. As this is a retrospective RWE study, we applied for a waiver of patient consent from the IRB (institutional review board, IRB) and approved to perform when we submit protocol approval to IRB. However, IRB/IEC of Samsung Medical Center recommended to proceed with the consent form for personal information. Thus, Samsung Medical Center received the subjects’ consents for personal information. Samsung Medical Center Institutional Review Board approved the study (approval number 2020–05-070). A list of the ethics committees that approved the study protocol are provided in Supplementary Table 1.